{"protocolSection": {"identificationModule": {"nctId": "NCT00460577", "orgStudyIdInfo": {"id": "CFOR258DVE02"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction", "officialTitle": "Randomized, Double Blind, Double Dummy, Placebo Controlled Trial to Compare the Effectiveness of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Asthmatic Children (5-<12 Years) With Acute Bronchial Obstruction Attending Emergency Services"}, "statusModule": {"statusVerifiedDate": "2011-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-03"}, "primaryCompletionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-04-13", "studyFirstSubmitQcDate": "2007-04-13", "studyFirstPostDateStruct": {"date": "2007-04-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-13", "resultsFirstSubmitQcDate": "2011-03-23", "resultsFirstPostDateStruct": {"date": "2011-04-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-03-23", "lastUpdatePostDateStruct": {"date": "2011-04-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To determine efficacy and tolerability of inhaled Formoterol vs nebulized Ipatropioum Bromide plus Fenoterol in cumulative sequential doses in asthmatic children (5-\\<12 years) with acute bronchial obstruction attending emergency services"}, "conditionsModule": {"conditions": ["Acute Bronchial Obstruction, Asthma"], "keywords": ["Asthma, Formoterol, Bronchial Obstruction, Children"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 60, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Formoterol (Foradil\u00ae)", "type": "ACTIVE_COMPARATOR", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae.", "interventionNames": ["Drug: Formoterol fumerate"]}, {"label": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg", "type": "ACTIVE_COMPARATOR", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized.", "interventionNames": ["Drug: fenoterol/ipratropium bromide"]}], "interventions": [{"type": "DRUG", "name": "Formoterol fumerate", "description": "12 micrograms stat (twice if necessary). Inhaled via aerolizer", "armGroupLabels": ["Formoterol (Foradil\u00ae)"]}, {"type": "DRUG", "name": "fenoterol/ipratropium bromide", "description": "0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.", "armGroupLabels": ["Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation", "description": "Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Maximum Expiratory Flow.", "timeFrame": "Baseline,4 hours"}, {"measure": "Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation", "description": "Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Forced Expiratory Volume in 1 second. FEV1 is defined as the volume of air that can be forced out of the lungs in 1 second after taking a deep breath.", "timeFrame": "Baseline,4 hours"}, {"measure": "Mean Change in Pulse Oxymetry From Baseline to Final Evaluation", "description": "Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Pulse Oximetry used to monitor the percentage of oxygen saturation of hemoglobin in the blood.", "timeFrame": "Baseline, 4 hours"}, {"measure": "Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation", "description": "Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by the Conway Clinical Scale. Assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.", "timeFrame": "Baseline,4 hours"}], "secondaryOutcomes": [{"measure": "Safety Assessed by: Pulse Oxymetry, Clinical Assessments, Adverse Events", "description": "Not posted: see comment in Limitations and Caveats.", "timeFrame": "4 hours"}, {"measure": "Pharmacoeconomic Analysis", "description": "Pharmacoeconomic analysis comparing the mean direct costs (total cost per prescription) of treatment with Formoterol (Foradil\u00ae) to treatment with Fenoterol 0.5 mg + Berodual\u00ae.", "timeFrame": "4 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Asthmatic children 5-\\<12 years old, requiring emergency services for acute bronchial obstruction mild to moderate determined by functional and clinical evidence\n\nExclusion Criteria:\n\n* Patients with severe acute bronchial obstruction determined by functional and clinical evidence\n* Patients unable to use the inhaling device at time of treatment\n* Patients who received a bronchodilator drug within the last 12 hours\n* Patients who received inhaled steroids within the last 72 hours\n* Patients who received systemic steroids within the last 7 days\n* Patients with near fatal asthma history\n* Patients with fever (\\>38.5\u00b0C axillar temp)\n* Patients with any clinical significance condition\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "5 Years", "maximumAge": "12 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis de Venezuela", "affiliation": "Novartis de Venezuela", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Novartis Investigator site - five sites in Caracas", "city": "Caracas", "country": "Venezuela", "geoPoint": {"lat": 10.48801, "lon": -66.87919}}, {"facility": "Novartis Investigator Site", "city": "Maracaibo", "country": "Venezuela", "geoPoint": {"lat": 10.66663, "lon": -71.61245}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Formoterol (Foradil\u00ae)", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae."}, {"id": "FG001", "title": "Fenoterol 0.5 mg + Berodual\u00ae", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "148 patients were screened; however, 22 did not consent and 66 did not meet inclusion/exclusion.", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Formoterol (Foradil\u00ae)", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae."}, {"id": "BG001", "title": "Fenoterol 0.5 mg + Berodual\u00ae", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "60"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "60"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.8", "spread": "1.5"}, {"groupId": "BG001", "value": "7.8", "spread": "2.1"}, {"groupId": "BG002", "value": "7.8", "spread": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "23"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}]}]}, {"title": "Maximum Inspiratory Flow", "description": "Mean of the Maximum Inspiratory Flow", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liters/minute", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "77.7", "spread": "16.7"}, {"groupId": "BG001", "value": "79.9", "spread": "17.5"}, {"groupId": "BG002", "value": "78.8", "spread": "0"}]}]}]}, {"title": "Maximum Expiratory Flow", "description": "Mean of Maximum Expiratory Flow", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liters/minute", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "140.3", "spread": "33.1"}, {"groupId": "BG001", "value": "150.3", "spread": "36.6"}, {"groupId": "BG002", "value": "145.3", "spread": "0"}]}]}]}, {"title": "Forced Expiratory Flow 1 sec", "description": "Mean of Forced Expiratory Flow one second (FEV1) defined as the volume of air that can be forced out in 1 second after taking a deep breath.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.06", "spread": "0.280"}, {"groupId": "BG001", "value": "1.12", "spread": "0.289"}, {"groupId": "BG002", "value": "1.09", "spread": "0"}]}]}]}, {"title": "Forced Expiratory Flow 1 sec as a Percentage of Predicted", "description": "Mean Expiratory Flow 1 second as a Percentage of Predicted", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage of Predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67.05", "spread": "15.22"}, {"groupId": "BG001", "value": "71.17", "spread": "15.76"}, {"groupId": "BG002", "value": "69.11", "spread": "0"}]}]}]}, {"title": "Conway Clinical Scale", "description": "Mean of Clinical Scale score measured by assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.1", "spread": "1.4"}, {"groupId": "BG001", "value": "4.0", "spread": "1.5"}, {"groupId": "BG002", "value": "4.05", "spread": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation", "description": "Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Maximum Expiratory Flow.", "populationDescription": "Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters/minute", "timeFrame": "Baseline,4 hours", "groups": [{"id": "OG000", "title": "Formoterol (Foradil\u00ae)", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae."}, {"id": "OG001", "title": "Fenoterol 0.5 mg + Berodual\u00ae", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44", "spread": "26.87"}, {"groupId": "OG001", "value": "43.67", "spread": "20.48"}]}]}]}, {"type": "SECONDARY", "title": "Safety Assessed by: Pulse Oxymetry, Clinical Assessments, Adverse Events", "description": "Not posted: see comment in Limitations and Caveats.", "reportingStatus": "NOT_POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 hours"}, {"type": "SECONDARY", "title": "Pharmacoeconomic Analysis", "description": "Pharmacoeconomic analysis comparing the mean direct costs (total cost per prescription) of treatment with Formoterol (Foradil\u00ae) to treatment with Fenoterol 0.5 mg + Berodual\u00ae.", "populationDescription": "Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Cost in US Dollars", "timeFrame": "4 hours", "groups": [{"id": "OG000", "title": "Formoterol (Foradil\u00ae)", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae."}, {"id": "OG001", "title": "Fenoterol 0.5 mg + Berodual\u00ae", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.21", "lowerLimit": "6.19", "upperLimit": "12.93"}, {"groupId": "OG001", "value": "25.67", "lowerLimit": "21.95", "upperLimit": "29.91"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation", "description": "Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Forced Expiratory Volume in 1 second. FEV1 is defined as the volume of air that can be forced out of the lungs in 1 second after taking a deep breath.", "populationDescription": "Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline,4 hours", "groups": [{"id": "OG000", "title": "Formoterol (Foradil\u00ae)", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae."}, {"id": "OG001", "title": "Fenoterol 0.5 mg + Berodual\u00ae", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.32", "spread": "0.2"}, {"groupId": "OG001", "value": "0.34", "spread": "0.22"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change in Pulse Oxymetry From Baseline to Final Evaluation", "description": "Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Pulse Oximetry used to monitor the percentage of oxygen saturation of hemoglobin in the blood.", "populationDescription": "Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage", "timeFrame": "Baseline, 4 hours", "groups": [{"id": "OG000", "title": "Formoterol (Foradil\u00ae)", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae."}, {"id": "OG001", "title": "Fenoterol 0.5 mg + Berodual\u00ae", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.57", "spread": "1.67"}, {"groupId": "OG001", "value": "2.83", "spread": "2.51"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation", "description": "Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by the Conway Clinical Scale. Assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.", "populationDescription": "Per protocol population: defined as number of patients who did not present any major deviations from protocol and received at least one dose of investigational study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline,4 hours", "groups": [{"id": "OG000", "title": "Formoterol (Foradil\u00ae)", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae."}, {"id": "OG001", "title": "Fenoterol 0.5 mg + Berodual\u00ae", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.18", "spread": "1.59"}, {"groupId": "OG001", "value": "-3.04", "spread": "1.83"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Formoterol (Foradil\u00ae)", "description": "Formoterol (Foradil\u00ae) 12 micrograms administered through Aerolizer\u00ae.", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 0, "otherNumAtRisk": 30}, {"id": "EG001", "title": "Fenoterol 0.5 mg + Berodual\u00ae", "description": "Fenoterol 0.5 mg + Ipratropium Bromide (Berodual\u00ae) 0.25 mg 20 drops in 3 mL of saline solution nebulized.", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 0, "otherNumAtRisk": 30}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Secondary Outcome Measure 2: Safety Assessed by Pulse Oxymetry, Clinical Assessments, Adverse Events has not been posted. Analysis of Pulse Oxymetry and Clinical Assessment was not performed. Adverse events are reported in the Adverse Event section."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7796", "name": "Emergencies", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001965", "term": "Bromides"}, {"id": "D000005280", "term": "Fenoterol"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000009241", "term": "Ipratropium"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000013566", "term": "Sympathomimetics"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "asFound": "Root", "relevance": "HIGH"}, {"id": "M12193", "name": "Ipratropium", "asFound": "Levonorgestrel", "relevance": "HIGH"}, {"id": "M8417", "name": "Fenoterol", "asFound": "Chronic neutrophilic leukemia", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "Repr", "name": "Reproductive Control Agents"}]}}, "hasResults": true}